Wavelength-Pharmaceuticals-Insert
X

Find Novel Drugs for Infections and Infectious Diseases under Discovery

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): mRNA vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Vaccine

            Partner/Sponsor/Collaborator: Sanofi

            Deal Size: $2,300.0 million Upfront Cash: $425.0 million

            Deal Type: Expanded Collaboration June 23, 2020

            Details:

            The two companies will build upon their existing collaboration to pursue novel mRNA vaccines aimed at broadly addressing current and future infectious diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Anti-SARS-CoV-2 S1 Antibody

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 28, 2020

            Details:

            The Twist anti-SARS-CoV-2 S1 Antibody Panel includes 32 human antibodies that bind with picomolar to nanomolar affinity to S1 spike protein on the SARS-CoV-2 virus.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Non-beta-lactam antibiotic

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: NIAID

            Deal Size: $44.2 million Upfront Cash: Undisclosed

            Deal Type: Funding July 27, 2020

            Details:

            Funding aims to advance a novel series of Penicillin Binding Protein (PBP) Inhibitors targeting multi-drug resistant (MDR) Acinetobacter baumannii through Phase 1 clinical testing.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Peptide

            Partner/Sponsor/Collaborator: Merck & Co. Inc.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 21, 2020

            Details:

            IRBM will leverage previous research into SARS to contribute to identifying and developing a potential treatment of SARS-CoV-2, as well as other future life-threatening coronavirus strains.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Plant-based COVID-19 antigen

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 15, 2020

            Details:

            Preliminary research results from ZYUS Life Sciences show that plant-based antigens are reactive to anti-COVID-19 antibodies and potentially offer immunity from COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Merck & Co. Inc.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 14, 2020

            Details:

            Hackensack Meridian CDI and Merck will work to discover drug candidates that can help treat Covid-19. Hackensack Meridian CDI will combine its expertise in academic drug discovery and viral pathogens analysis with Merck’s capabilities to discover and develop anti-infectives.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Merck & Co. Inc.

            Deal Size: Undisclosed Upfront Cash: $305.0 million

            Deal Type: Collaboration July 13, 2020

            Details:

            Merck will apply Dewpoint’s proprietary platform for condensate-based drug discovery for the development of a novel mechanism to treat HIV.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Medivir

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership July 06, 2020

            Details:

            The aim of the collaboration is to find potential inhibitors of the main protease of SARS CoV-2, an essential non-structural protein, Mpro, required for virus replication.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): RBI-5000

            Therapeutic Area: Infections and Infectious Diseases Product Name: RBI-5000

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Replicate Bioscience

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement June 24, 2020

            Details:

            ITI and Replicate will develop candidates combining ITI’s UNITE technology with Replicate’s scalable self-replicating RNA (SynRGY technology) for COVID-19, HPV, and EBV.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 11, 2020

            Details:

            Using the AbiprotTM antibody discovery platform, a team of researchers has identified a potentially important epitope in SARS-CoV-2 that may facilitate generation of neutralizing antibodies to treat Covid-19 patients.

            PharmaCompass